glp 1 gip agonists TrimRX LY3437943, a novel triple glucagon,
Description
Comparative effectiveness of glucagon-like peptide-1 receptor agonists and other second-line glucose-lowering agents for dementia outcomes in type 2 diabetes mellitus: A cohort study

Some patients report ongoing symptoms such as persistent nausea, vomiting, abdominal pain, and delayed gastric emptying that do not resolve after discontinuation

Expert Rev Endocrinol Metab 2025;20:147-52.ArticlePubMed 96
Once discontinued, many patients experience appetite rebound, making sustained weight loss challenging

Retrieved from Diabetes Prevention Program Research Group
326 , E268e276 (2024)